Ignite Creation Date:
2024-05-06 @ 2:28 PM
Last Modification Date:
2024-10-26 @ 1:31 PM
Study NCT ID:
NCT04324255
Status:
UNKNOWN
Last Update Posted:
2020-03-27
First Post:
2020-03-21
Brief Title:
Von Willebrand Factor and Protein C Ratio in Graft Function After Liver Transplant
Sponsor:
Asan Medical Center
Organization:
Asan Medical Center
Study Overview
Official Title:
Von Willebrand Factor and Protein c Ratio-related Thrombogenicity With Systemic Inflammation is Predictive of Graft Dysfunction After Liver Transplantation Retrospective Cohort Study
Status:
UNKNOWN
Status Verified Date:
2020-03
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In liver cirrhosis LCthe activity of von Willebrand factor vWF-cleaving enzyme ADAMTS13 is reduced in LC patients and consequent progression of liver injury Remarkably it has been reported that a severe vWFADAMTS13 imbalance develops during liver transplantation LT and persists even after LT Such changes are thought to contribute to postoperative thrombotic complications which may lead to early adverse events of thrombotic microangiopathy after living-donor LT LDLT We investigated whether vWFPCR could predict EAD or graft failure following LT and compared it with FVIIIPCR procoagulant such as vWF and FVIII and anticoagulant such as PC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None